Amrita Ahluwalia is the Dean for Research and Research
Impact (Faculty of Medicine & Dentistry), Lead of The Vascular Pharmacology
Group, and Director of the Barts Cardiovascular Clinical Trials Unit at Queen
Mary University of London. Separately, she is the Chair of the Basic and
Translational Section of The International Union of Basic and Clinical
Pharmacology. She obtained a BSc in Pharmacology from Bath University and
undertook doctoral training at the William Harvey Research Institute (WHRI). In
the mid-nineties she worked at St George’s Hospital Medical School with
Professor Patrick Vallance followed by University College London as a Lecturer
before returning to the WHRI where she is currently a Professor of Vascular
Pharmacology. She was the Deputy Director of the WHRI from 2013–2016 and then
Director from 2016–2020. Her interests revolve around developing therapeutics
targeting inflammation in the cardiovascular system for which she has won
awards (e.g., the GSK Prize in Clinical Pharmacology 2012 and the WISE 2015
Prize for Research). The main research focus of her group is the exploration of
the impact of inflammation on cardiovascular function and the mechanisms
involved in this phenomenon with a view to identifying novel targets and therapeutics.
Amrita Ahluwalia is the Dean for Research and Research
Impact (Faculty of Medicine & Dentistry), Lead of The Vascular Pharmacology
Group, and Director of the Barts Cardiovascular Clinical Trials Unit at Queen
Mary University of London. Separately, she is the Chair of the Basic and
Translational Section of The International Union of Basic and Clinical
Pharmacology. She obtained a BSc in Pharmacology from Bath University and
undertook doctoral training at the William Harvey Research Institute (WHRI). In
the mid-nineties she worked at St George’s Hospital Medical School with
Professor Patrick Vallance followed by University College London as a Lecturer
before returning to the WHRI where she is currently a Professor of Vascular
Pharmacology. She was the Deputy Director of the WHRI from 2013–2016 and then
Director from 2016–2020. Her interests revolve around developing therapeutics
targeting inflammation in the cardiovascular system for which she has won
awards (e.g., the GSK Prize in Clinical Pharmacology 2012 and the WISE 2015
Prize for Research). The main research focus of her group is the exploration of
the impact of inflammation on cardiovascular function and the mechanisms
involved in this phenomenon with a view to identifying novel targets and therapeutics.